Drugs / BR101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07537049 | Apr 2026 → Apr 2027 expected | plasma cell myeloma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06001580 | Aug 2021 → Oct 2023 | neoplasm | BioRay Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06001580 ↗ |
| Modality | Cell therapy | “In vivo BCMA/CD19 bi-specific Chimeric Antigen Receptor (CAR) T Cell Therapy” NCT07537049 ↗ |
| Route | Intravenous | “after intravenous administration” NCT07537049 ↗ |